Limba:
Moneda:

1 000 000 de clienți au ales uimitorul nostru serviciu și produsele de înaltă calitate

  • Economisește până la 80%

    Reduceri mari și lichidări de stoc

  • Livrare rapidă și în întreaga lume

    Primești comanda rapid

  • Nu e nevoie de rețetă

    Cumperi pastile fără restricții

  • Garantat banii înapoi

    30 de zile timp de returnare

Doctor
Coșul tău de cumpărături este gol

Farmacie verificată

Mai bine de 100 de certificate aprobate

  • fda
  • fda
  • pgeu gpue
  • mipa
  • cipar
  • mastercard
  • visa
  • mcafee

Banners

Movfor

movfor
  • Movfor 200mg

    Pachet Per Pastilă Preț Special
    200 capsule Livrare Expres Gratuită $5.49 $1466 -26% Doar $1097
    160 capsule Livrare Expres Gratuită $5.60 $1173 -24% Doar $896
    120 capsule Livrare Expres Gratuită $5.79 $880 -21% Doar $695
    80 capsule Livrare Expres Gratuită $6.18 $587 -16% Doar $494
    40 capsule Livrare Standard Gratuită $7.33 Doar $293

Product Description

Common use
Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

Dosage and direction

Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days.
Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

Results

Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

Conclusions

Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

Vă poate plăcea și:

Abonati-va Oferte speciale și știri
Abonati-va

testimonials

    5 stars

Andrei Popescu “Niciodată n-am fost mai mulțumit de un serviciu online. Livrarea a fost rapidă, și totul a fost simplu de folosit.”

Următoarele Testimoniale